Company Overview and News

1
CYD / China Yuchai International, Ltd FORM 20-F

2018-04-16 sec.gov
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
BRIEF-MTU Yuchai Power Commences Mass Production Of MTU S4000 Series Engines

2018-04-16 reuters
* CHINA YUCHAI INTERNATIONAL - UNIT MTU YUCHAI POWER COMMENCED PRODUCTION OF MTU S4000 SERIES ENGINES IN ITS NEW FACILITY IN YULIN CITY, CHINA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Upvote Downvote

9
13 Exclusive Investment Ideas For 2018

2018-03-09 seekingalpha
Pressing them for their top ideas for the rest of 2018, I was able secure 13 of their top ideas.
Upvote Downvote

 
China Yuchai (CYD) Presents At Evercore ISI Annual Industrial Conference - Slideshow

2018-03-08 seekingalpha
The following slide deck was published by China Yuchai International Limited in conjunction with this event.
Upvote Downvote

 
China Yuchai International Limited's (CYD) Management on Q4 2017 Results - Earnings Call Transcript

2018-02-27 seekingalpha
China Yuchai International Limited (NYSE:CYD) Q4 2017 Earnings Conference Call February 27, 2018 8:00 AM ET
Upvote Downvote

 
CYD / China Yuchai International, Ltd FORM 6-K (Current Report of Foreign Issuer)

2018-02-27 sec.gov
cyd-6k_20180227.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2018 (Commission File No. 1 - 13522) CHINA YUCHAI INTERNATIONAL LIMITED (Translation of registrant’s name into English) 16 Raffles Quay #26-00 Hong Leong Building Singapore 048581 (Address of registrant’s principal executive office) Indicate by check mark whether the registrant files or
Upvote Downvote

 
CYD / China Yuchai International, Ltd 6-K (Current Report of Foreign Issuer)

2018-02-13 sec.gov
cyd-6k_20180213.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K   REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2018 (Commission File No. 1 - 13522)   CHINA YUCHAI INTERNATIONAL LIMITED (Translation of registrant’s name into English)   16 Raffles Quay #26-00 Hong Leong Building Singapore 048581 (Address of registrant’s principal executive office)   Indicate by check mark whether the regis
Upvote Downvote

 
CYD / China Yuchai International, Ltd 6-K (Current Report of Foreign Issuer)

2018-01-23 sec.gov
cyd-6k_20180123.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K   REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 23, 2018 (Commission File No. 1 - 13522)   CHINA YUCHAI INTERNATIONAL LIMITED (Translation of registrant’s name into English)   16 Raffles Quay #26-00 Hong Leong Building Singapore 048581 (Address of registrant’s principal executive office)   Indicate by check mark whether the regist
Upvote Downvote

2
Shah Capital Management - All Holdings - 13F 13D 13G Filings - Fintel.io

2018-01-03 fintel.io
Shah Capital Management has disclosed 13 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 198,749,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Shah Capital Management's top holdings are China Yuchai International, Ltd (NYSE:CYD) , Genworth Financial, Inc. (NYSE:GNW) , Avon Products, Inc. (NYSE:AVP) , VEON Ltd.
Upvote Downvote

 
BRIEF-China Yuchai Announces Increase Of Shareholding In Subsidiary

2018-01-02 reuters
* CHINA YUCHAI INTERNATIONAL - TOTAL CONSIDERATION FOR ACQUISITION WAS RMB6.7 MILLION, WHICH WAS SATISFIED IN CASH AND FUNDED THROUGH INTERNAL RESOURCES
Upvote Downvote

 
CYD / China Yuchai International, Ltd LIVE FILING (Current Report of Foreign Issuer)

2017-12-01 sec.gov
China Yuchai International Limited - Form 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 1, 2017 Commission File Number: 1-13522 China Yuchai International Limited ——————————————————————————————————— (Translation of registrant’s name into English)   16 Raffles Quay #26-00 Hong Leong Building Singapore 048581 ———————————————————————————————
Upvote Downvote

 
Wired News – A Subsidiary of China Yuchai Acquires China's Jining Yuchai Engine Company

2017-11-30 accesswire
LONDON, UK / ACCESSWIRE / November 30, 2017 / issued a free report on China Yuchai International Ltd (NYSE: CYD), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=CYD as the Company’s latest news hit the wire. On November 28, 2017, the Company announced that its main operating subsidiary, Guangxi Yuchai Machinery Company Limited (GYMCL), has acquired all the issued shares in Jining Yuchai Engine Company Limited (Jining Yuchai), a China based Company that develops, produces, and sells 4D2.
Upvote Downvote

 
CYD / China Yuchai International, Ltd FORM 6-K (Current Report of Foreign Issuer)

2017-11-13 sec.gov
Form 6-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 6-K     REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 13, 2017 Commission File Number 1—13522     China Yuchai International Limited (Translation of Registrant’s name into English)     16 Raffles Quay #26-00 Hong Leong Building Singapore 048581 (Address of principal executive offices)     Indicate by check mark whether the registran
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: G21082105